Financings in Brief: Thoratec
This article was originally published in The Gray Sheet
Thoratec: Plans private placement of 2 mil. shares -- including 1.5 mil. to be offered by the company and 500,000 to be offered by a selling shareholder -- to "selected institutional investors." Vector Securities International and Cruttenden Roth are placement agents for the proposed offering...
You may also be interested in...
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.